Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesOrthopedics/MusculoskeletalCareFirst PES knee osteoarthritis Coverage Update …
    Ask Trek AI about this page
    CurrentCareFirstPolicy N/A

    Pulsed Electrical Stimulation Device for Osteoarthritis of the Knee

    Customize your policy alerts

    Sign up for all CareFirst policy alerts

    Know when CareFirst releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines CareFirst coverage stance for pulsed electrical stimulation (PES) devices (e.g., BioniCare/BIO-1000) used to treat osteoarthritis of the knee for members covered under CareFirst plans.

    Policy Summary
    PayerCareFirst
    PolicyPulsed Electrical Stimulation Device for Osteoarthritis of the Knee
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateFeb 1, 2026
    Last ReviewNov 12, 2025
    Next Review DateNov 12, 2025
    Key ActionCheck the Prior Authorization Look-up tool (PAL) or call the CareFirst preauthorization number before providing services or devices.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    experimentalcoverage stance for PES devices
    FDA 510(k)

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    regulatory status
    2008-2025literature surveillance
    1 studylonger non-randomized study

    Coverage Determination

    Coverage determination

    Covered when ALL of the following are met

    Policy stance: Pulsed electrical stimulation devices for treatment of osteoarthritis of the knee are considered experimental/investigational and therefore not covered because they do not meet the BlueCross BlueShield Association MPS/TEC criteria #2-5.

    Policy statement from CareFirst

    Regulatory status: The BIO-1000 device has FDA 510(k) clearance as an adjunctive therapy for reducing pain and symptoms associated with knee osteoarthritis (May 9, 2003), but clearance alone does not satisfy the TEC criteria for final approval required for coverage.

    Regulatory rationale

    Evidence adequacy: Scientific evidence is insufficient to permit conclusions about the effect of PES on long-term health outcomes due to small, short-term, heterogeneous studies and lack of standardized outcome measures.

    Evidence limitations summarized in rationale

    Net health outcome: There is inadequate evidence that PES improves net health outcomes or reliably delays or obviates the need for total knee replacement; available longer-term data lack randomization and use historical controls.

    Mont et al. 4-year study limitations

    Effectiveness vs alternatives: PES has not been demonstrated to be as effective as established alternatives; FDA clearance described PES as adjunctive and no comparative randomized trials show equivalence to standard treatments.

    Adjunctive status and lack of comparative evidence

    Generalizability: Reported improvements have not been shown to be attainable outside investigational settings because studies involved small groups, short durations, and methodologic limitations.

    External validity concerns and periodic literature surveillance with no change in conclusions

    Pulsed electrical stimulation (PES) devices for treatment of osteoarthritis of the knee are excluded from coverage and considered experimental/investigational.

    Use of PES devices for knee osteoarthritis is regarded as not medically necessary/experimental because available evidence is insufficient to demonstrate long‑term net health benefit or equivalence to established alternatives. Clinical studies have been small, short‑term, or nonrandomized, with inconsistent outcomes and limited data on meaningful measures such as joint swelling, range of motion, walking time, and delay of total knee replacement. Periodic literature surveillance (most recently through 2025) found no new evidence to change this conclusion.

    Provider Requirements and Actions

    Prior Authorization

    Prior authorization required — verify before providing PES devices/services

    Check the Prior Authorization Look-up tool (PAL) or call the CareFirst preauthorization number before providing services or devices to confirm whether prior authorization is required for the proposed PES device or related services.

    • Use the PAL Tool: https://provider.carefirst.com/providers/medical/in-network-precertification-preauthorization.page
    • Or call 1-866-773-2884 (1-866-PRE-AUTH)
    Step Therapy

    No step therapy specified; FDA calls PES adjunctive but comparative evidence lacking

    No step therapy protocols for PES devices are specified in this policy; the BIO-1000 is cleared by the FDA as an adjunctive therapy but the policy notes there are no comparative studies demonstrating equivalence to established alternatives.

    • PES described by FDA clearance as “adjunctive” therapy

    Device Definition

    Pulsed electrical stimulation (PES) device / BIO-1000 / BioniCare — key attributes
    Device typeWearable system consisting of a signal generator and fabric wrap applicator
    Applicator designFabric wrap resembling a knee brace with two contact elements (electrodes) inside; secured with Velcro straps
    Stimulation waveformLow‑amplitude negative monophasic pulsed electrical field (negative monophasic pulses)
    Application methodConductive electrode gel applied to contact elements; lead wire connects applicator to signal generator
    Usage patternDesigned to be worn continuously for several hours per day; voltage set just below tingling threshold
    Intended effects (manufacturer claim)Provides symptomatic relief and may delay need for surgery or promote cartilage growth (manufacturer claim)

    Background and Evidence Summary

    Pulsed electrical stimulation (PES) systems (for example, the BIO-1000/BioniCare) are wearable devices that deliver low‑amplitude monophasic pulsed electrical fields to the knee through skin‑contact applicators; they are intended as an adjunctive, symptomatic therapy that may be worn for multiple hours daily. Clinical evaluations have reported outcomes such as pain and physician global assessment, but trials have generally been small, of short duration, or nonrandomized; one longer nonrandomized study used historical controls and was subject to confounding. Overall, the evidence is inconsistent and does not adequately demonstrate sustained improvement in OA symptoms or prevention/delay of total knee replacement.

    Policy Summary
    PayerCareFirst
    PolicyPulsed Electrical Stimulation Device for Osteoarthritis of the Knee
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateFeb 1, 2026
    Last ReviewNov 12, 2025
    Next Review DateNov 12, 2025
    Key ActionCheck the Prior Authorization Look-up tool (PAL) or call the CareFirst preauthorization number before providing services or devices.
    SourceLink
    On This Page
    Coverage DeterminationProvider Requirements and ActionsDevice DefinitionBackground and Evidence Summary
  1. Policy states insufficient evidence from comparative studies to show PES is as effective as alternatives
  2. Documentation Required

    Confirm member contract and prior authorization requirements

    Verify the member’s contract benefits and prior authorization requirements using CareFirst resources; specific contract provisions or exclusions take precedence over clinical criteria.

    • Always check the member’s contract for benefits — contract supersedes clinical criteria
    • For prior authorization requirements use the PAL Tool or call 1-866-773-2884
    Denial Risk

    Denial risk — PES devices for OA knee considered experimental/investigational

    Requests for pulsed electrical stimulation (PES) devices for treatment of osteoarthritis of the knee will be denied as experimental/investigational under this policy.

    • Policy statement: PES devices for OA knee are considered experimental/investigational and not covered